Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

3.015 +0.095 (+3.25%)
Streaming Delayed Price Updated: 1:16 PM EDT, Sep 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 121,529
Open 2.930
Bid (Size) 3.010 (500)
Ask (Size) 3.020 (100)
Prev. Close 2.920
Today's Range 2.930 - 3.109
52wk Range 1.210 - 3.600
Shares Outstanding 40,501,258
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Acumen Pharmaceuticals Q2 Earnings Call Highlights ↗
Acumen Pharmaceuticals (NASDAQ:ABOS) said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to... 
Via MarketBeat
Topics Earnings
News headline image
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+49.3%
+49.3%
1 Month
+38.3%
+38.3%
3 Month
+27.2%
+27.2%
6 Month
-8.9%
-8.9%
1 Year
+121.7%
+121.7%

More News

Read More
News headline image
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals (NASDAQ:ABOS) Q1 2026 Loss Narrows as Phase 2 Alzheimer's Trial Readout Looms ↗
Via Chartmill
Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Narrower-Than-Expected Q4 Loss, Provides Key Clinical Update ↗
Via Chartmill
News headline image
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen (ABOS) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Acumen Pharmaceuticals Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
These stocks have an unusual volume in today's session ↗
Via Chartmill
Tuesday's after hours session: top gainers and losers ↗
Via Chartmill
The market is filled with gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Acumen Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Acumen Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Acumen Pharmaceuticals, Inc. - Common Stock trade on?
Acumen Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Acumen Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Acumen Pharmaceuticals, Inc. - Common Stock is ABOS on the Nasdaq Stock Market
What is the current price of Acumen Pharmaceuticals, Inc. - Common Stock?
The current price of Acumen Pharmaceuticals, Inc. - Common Stock is 3.015
When was Acumen Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Acumen Pharmaceuticals, Inc. - Common Stock was at 09/02/26 01:16 PM ET
What is the market capitalization of Acumen Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Acumen Pharmaceuticals, Inc. - Common Stock is 122.11M
How many shares of Acumen Pharmaceuticals, Inc. - Common Stock are outstanding?
Acumen Pharmaceuticals, Inc. - Common Stock has 122M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.